Identification of new 4-(6-oxopyridazin-1-yl)benzenesulfonamides as multi-target anti-inflammatory agents targeting carbonic anhydrase, COX-2 and 5-LOX enzymes: synthesis, biological evaluations and modelling insights.

Carbonic Anhydrases / metabolism Molecular Structure Structure-Activity Relationship Carbonic Anhydrase IX / metabolism Cyclooxygenase 2 / metabolism Sulfonamides / chemistry Anti-Inflammatory Agents / pharmacology Carbonic Anhydrase Inhibitors / chemistry Benzenesulfonamides
Analgesic Molecular modelling Pyridazinone Sulphonates Synthesis

Journal

Journal of enzyme inhibition and medicinal chemistry
ISSN: 1475-6374
Titre abrégé: J Enzyme Inhib Med Chem
Pays: England
ID NLM: 101150203

Informations de publication

Date de publication:
Dec 2023
Historique:
medline: 21 4 2023
pubmed: 20 4 2023
entrez: 20 04 2023
Statut: ppublish

Résumé

Multiple inhibitions of CA, COX-2 and 5-LOX enzymes has been recognised as a useful strategy for the development of anti-inflammatory drugs that can avoid the disadvantages of using NSAIDs alone. Here, we report new pyridazine-based sulphonamides (

Identifiants

DOI: 10.1080/14756366.2023.2201407 PMID: 37078173 PMC: PMC10120535
pubmed: 37078173
doi: 10.1080/14756366.2023.2201407
pmc: PMC10120535
doi:

Substances chimiques

Carbonic Anhydrases EC 4.2.1.1
Carbonic Anhydrase IX EC 4.2.1.1
Cyclooxygenase 2 EC 1.14.99.1
Sulfonamides 0
Anti-Inflammatory Agents 0
Carbonic Anhydrase Inhibitors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2201407

Références

Biochem J. 2016 Jul 15;473(14):2023-32
pubmed: 27407171
Bioorg Med Chem Lett. 2013 Apr 1;23(7):2007-13
pubmed: 23453843
BMC Musculoskelet Disord. 2012 Dec 20;13:256
pubmed: 23256642
Int J Mol Sci. 2020 Apr 07;21(7):
pubmed: 32272689
Bioorg Chem. 2022 Dec;129:106171
pubmed: 36166898
J Biol Chem. 1971 Apr 25;246(8):2561-73
pubmed: 4994926
Eur J Med Chem. 2021 Dec 5;225:113804
pubmed: 34479036
Clin Exp Rheumatol. 1985 Apr-Jun;3(2):99-104
pubmed: 4017318
BMC Musculoskelet Disord. 2010 Dec 08;11:279
pubmed: 21143847
Metabolites. 2020 Oct 14;10(10):
pubmed: 33066524
Bioorg Med Chem Lett. 2006 Jan 15;16(2):437-42
pubmed: 16290146
Mini Rev Med Chem. 2016;16(12):996-1012
pubmed: 27290912
Pharmacol Ther. 2021 Sep;225:107860
pubmed: 33895188
Bioorg Med Chem Lett. 2016 Feb 15;26(4):1337-41
pubmed: 26804228
Arch Pharm (Weinheim). 2017 Sep;350(9):
pubmed: 28792072
Prostaglandins Other Lipid Mediat. 2011 Nov;96(1-4):27-36
pubmed: 21864702
Eur J Med Chem. 2020 Dec 1;207:112745
pubmed: 32877804
Molecules. 2022 Jun 10;27(12):
pubmed: 35744876
Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9545-50
pubmed: 11493685
Eur J Med Chem. 2018 Feb 25;146:139-146
pubmed: 29407945
Arch Pharm (Weinheim). 2020 Mar;353(3):e1900295
pubmed: 31944384
J Enzyme Inhib Med Chem. 2016;31(sup4):60-63
pubmed: 27539792
Anticancer Agents Med Chem. 2013 Sep;13(7):1133-40
pubmed: 23574386
Drug Discov Today. 2014 Dec;19(12):1871-82
pubmed: 25172801
Bioorg Med Chem. 2017 Apr 1;25(7):2210-2217
pubmed: 28256371
Nucleic Acids Res. 2021 Jan 8;49(D1):D437-D451
pubmed: 33211854
Eur J Med Chem. 2021 Apr 15;216:113283
pubmed: 33667848
J Enzyme Inhib Med Chem. 2019 Dec;34(1):1457-1464
pubmed: 31411080
Biochem Biophys Res Commun. 2016 Sep 9;478(1):1-6
pubmed: 27475498
Eur J Med Chem. 2016 Nov 10;123:256-281
pubmed: 27484513
Acta Crystallogr D Biol Crystallogr. 2010 May;66(Pt 5):616-27
pubmed: 20445237
Eur J Med Chem. 2019 Jun 1;171:25-37
pubmed: 30904755
J Med Chem. 2017 Feb 9;60(3):1159-1170
pubmed: 28075587
Expert Opin Investig Drugs. 2021 Dec;30(12):1197-1208
pubmed: 34865569
Eur J Med Chem. 2020 Mar 15;190:112112
pubmed: 32044580
J Enzyme Inhib Med Chem. 2021 Dec;36(1):1702-1714
pubmed: 34325588
Arch Pharm (Weinheim). 2022 Aug;355(8):e2200067
pubmed: 35532263
J Enzyme Inhib Med Chem. 2021 Dec;36(1):1988-1995
pubmed: 34482770
Proc Soc Exp Biol Med. 1962 Dec;111:544-7
pubmed: 14001233
J Pharmacol Pharmacother. 2012 Oct;3(4):348
pubmed: 23326113
Drug Discov Today. 2013 May;18(9-10):495-501
pubmed: 23340113
ACS Med Chem Lett. 2015 Jan 19;6(3):292-5
pubmed: 25815148
Curr Pharm Des. 2008;14(7):603-14
pubmed: 18336305
Eur J Pharm Sci. 2018 Jun 5;121:356-381
pubmed: 29883727
Protein Pept Lett. 2015;22(10):903-12
pubmed: 26095375
ACS Med Chem Lett. 2020 Mar 18;11(5):1022-1027
pubmed: 32435420
Clin Pharmacol Drug Dev. 2013 Oct;2(4):379-86
pubmed: 27121942
J Med Chem. 2015 Nov 25;58(22):9004-9
pubmed: 26522624
Future Med Chem. 2017 Jan;9(1):95-127
pubmed: 27957866
Eur J Med Chem. 2023 Mar 15;250:115180
pubmed: 36796297
J Neurosci. 1995 May;15(5 Pt 2):3982-9
pubmed: 7751959
Eur J Med Chem. 2019 Apr 15;168:301-314
pubmed: 30826507
J Enzyme Inhib Med Chem. 2016;31(3):345-60
pubmed: 26619898
J Med Chem. 2004 Jan 29;47(3):550-7
pubmed: 14736236
Front Chem. 2019 Feb 18;7:71
pubmed: 30834243
Clin Dev Immunol. 2012;2012:354594
pubmed: 23049597

Auteurs

Waleed A Badawi (WA)

Department of Pharmaceutical Chemistry, Damanhour University, Damanhour, Buhaira, Egypt.

Mahmoud Rashed (M)

Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.

Alessio Nocentini (A)

Department of Neurofarba, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Firenze, Sesto Fiorentino, Italy.
Department of Neurofarba, Section of Pharmaceutical and Nutraceutical Sciences, Laboratory of Molecular Modeling Cheminformatics & QSAR, University of Florence, Polo Scientifico, Firenze, Sesto Fiorentino, Italy.

Alessandro Bonardi (A)

Department of Neurofarba, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Firenze, Sesto Fiorentino, Italy.
Department of Neurofarba, Section of Pharmaceutical and Nutraceutical Sciences, Laboratory of Molecular Modeling Cheminformatics & QSAR, University of Florence, Polo Scientifico, Firenze, Sesto Fiorentino, Italy.

Mohammad M Abd-Alhaseeb (MM)

Department of Pharmacology and Toxicology, Damanhour University, Damanhour, Buhaira, Egypt.

Sara T Al-Rashood (ST)

Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.

Giri Babu Veerakanellore (GB)

Center for Clinical Pharmacology, Washington University School of Medicine and University of Health Sciences and Pharmacy, St. Louis, MO, USA.

Taghreed A Majrashi (TA)

Department of Pharmacognosy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.

Eslam B Elkaeed (EB)

Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Riyadh, Saudi Arabia.

Bahaa Elgendy (B)

Center for Clinical Pharmacology, Washington University School of Medicine and University of Health Sciences and Pharmacy, St. Louis, MO, USA.
Chemistry Department, Faculty of Science, Benha University, Benha, Egypt.

Paola Gratteri (P)

Department of Neurofarba, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Firenze, Sesto Fiorentino, Italy.
ORCID: 0000-0002-9137-2509

Claudiu T Supuran (CT)

Department of Neurofarba, Section of Pharmaceutical and Nutraceutical Sciences, Laboratory of Molecular Modeling Cheminformatics & QSAR, University of Florence, Polo Scientifico, Firenze, Sesto Fiorentino, Italy.
ORCID: 0000-0003-4262-0323

Wagdy M Eldehna (WM)

Department of Pharmaceutical Chemistry, Kafrelsheikh University, Kafrelsheikh, Egypt.
ORCID: 0000-0001-6996-4017

Mohamed Elagawany (M)

Department of Pharmaceutical Chemistry, Damanhour University, Damanhour, Buhaira, Egypt.

Articles similaires

Overcoming multi-drug resistance in SCLC: a synergistic approach with venetoclax and hydroxychloroquine targeting the lncRNA LYPLAL1-DT/BCL2/BECN1 pathway.

Shuxin Li, Jianyi Lv, Zhihui Li et al.
1.00
Humans Small Cell Lung Carcinoma RNA, Long Noncoding Sulfonamides Animals

Yu Hu, Liu-Lin Chen, Zhen Ye et al.
1.00
Colitis, Ulcerative Humans Animals Drugs, Chinese Herbal Anti-Inflammatory Agents

Single-cell landscape of innate and acquired drug resistance in acute myeloid leukemia.

Rebekka Wegmann, Ximena Bonilla, Ruben Casanova et al.
1.00
Humans Leukemia, Myeloid, Acute Drug Resistance, Neoplasm Single-Cell Analysis Sulfonamides

Impact of CA9 expression in the diagnosis of lymph-node metastases in non-small cell lung cancer based on [18F]FDG PET/CT.

Satoshi Suzuki, Masakazu Yashiro, Nobuhiro Izumi et al.
1.00
Humans Carcinoma, Non-Small-Cell Lung Male Fluorodeoxyglucose F18 Female

Classifications MeSH

questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Lyases › Carbon-oxygen lyases › Hydro-lyases › Carbonic anhydrases › Identification of new...
questionsmedicales.fr › Phénomènes chimiques › Structure moléculaire › Identification of new...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Relation structure-activité › Identification of new...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Antigènes néoplasiques › Carbonic anhydrase IX › Identification of new...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Complexes multienzymatiques › Cyclooxygenase 2 › Identification of new...
questionsmedicales.fr › Composés chimiques organiques › Composés du soufre › Sulfones › Sulfonamides › Identification of new...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-inflammatoires › Identification of new...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de l'anhydrase carbonique › Identification of new...